Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | CXCR5 | P32302 | 10/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929037 | 0.84 | GSK3B (0.35) | ADRA2ADPP9DPP8DPP7NOTUM | |
| SCHEMBL936918 | 0.83 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CADRA1BCXCR5 | |
| SCHEMBL856751 | 0.81 | MME (0.40) | ADRA2AADRA2BADRA2CADRA1BPTPN1 | |
| SCHEMBL30645250 | 0.81 | MME (0.40) | ADRA2AADRA2BADRA2CADRA1BPTPN1 | |
| SCHEMBL24440177 | 0.75 | CXCR5 (0.41) | ADRA2AADRA2BADRA2CADRA1BCXCR5 | |
| SCHEMBL27618127 | 0.73 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1BCXCR5 | |
| SCHEMBL9527248 | 0.72 | ATM (0.39) | — | |
| SCHEMBL21490402 | 0.70 | CXCR5 (0.37) | ADRA2AADRA2BADRA2CADRA1BCXCR5 | |
| SCHEMBL21490376 | 0.70 | CXCR5 (0.37) | ADRA2AADRA2BADRA2CADRA1BCXCR5 | |
| SCHEMBL29443108 | 0.70 | CXCR5 (0.37) | ADRA2AADRA2BADRA2CADRA1BCXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459540-A2 | PREPARATION OF FIPAMEZOLE | Dr. Reddy's Laboratories, Ltd. (IN) | 2012-06-06 | — | — | EP | claimed |
| US-20120130084-A1 | PREPARATION OF FIPAMEZOLE | DR. REDDY'S LABORATORIES, INC. (US) | 2012-05-24 | — | — | US | claimed |
| WO-2011014613-A2 | PREPARATION OF FIPAMEZOLE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-03 | — | — | WO | claimed |
| EP-2459540-A2 | PREPARATION OF FIPAMEZOLE | Dr. Reddy's Laboratories, Ltd. (IN) | 2012-06-06 | — | — | EP | disclosed |
| US-20120130084-A1 | PREPARATION OF FIPAMEZOLE | DR. REDDY'S LABORATORIES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130084-A1 | PREPARATION OF FIPAMEZOLE | DR. REDDY'S LABORATORIES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130084-A1 | PREPARATION OF FIPAMEZOLE | DR. REDDY'S LABORATORIES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2011014613-A2 | PREPARATION OF FIPAMEZOLE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014613-A2 | PREPARATION OF FIPAMEZOLE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-03 | — | — | WO | disclosed |
| EP-1581504-B1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS | JUVANTIA PHARMA LTD OY (FI) | 2009-03-18 | — | — | EP | disclosed |
| US-7223871-B2 | Process for preparing substituted imidazole derivatives and intermediates used in the process | OY JUVANTIA PHARMA LTD. (FI) | 2007-05-29 | — | — | US | disclosed |
| US-20060025465-A1 | Process for preparing substituted imidazole derivates and intermediates used in the process | OY JUVANTIA PHARMA LTD (FI) | 2006-02-02 | — | — | US | disclosed |
| EP-1581504-A1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS | Oy Juvantia Pharma Ltd (FI) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063168-A1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS | OY JUVANTIA PHARMA LTD (FI) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025465-A1 | Process for preparing substituted imidazole derivates and intermediates used in the process | HRH2, HRH4, HRH3 | ADRA2A 688/4885ADRA2B 782/4885ADRA2C 1118/4885 |
| US-20120130084-A1 | PREPARATION OF FIPAMEZOLE | FIP1L1, CYP3A7, CYP3A4 | ADRA2A 2590/4885ADRA2B 2015/4885ADRA2C 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.